← Back to Search

Monoclonal Antibodies

KN046 for Thymic Carcinoma

Phase 2

Waitlist Available

Led By Giuseppe Giaccone, MD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion (an average of 2 years)

Awards & highlights

Study Summary

This trial will test a new drug, KN046, on patients with a specific type of cancer that has progressed after other treatments. The goal is to see if it is safe and effective.

Eligible Conditions

Thymic Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion (an average of 2 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion (an average of 2 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (an average of 2 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Anti-tumor activity of KN046 in subjects with thymic carcinoma, determined by subject disease response rate defined by the RECIST 1.1 criteria.

Secondary outcome measures

Duration of response for KN046 in subjects with thymic carcinoma, determined by subject disease response rate defined by the RECIST 1.1 criteria.

Overall Survival (OS) for KN046 in subjects with thymic carcinoma, determined by subject disease response rate defined by the RECIST 1.1 criteria.

Progression Free Survival (PFS) for KN046 in subjects with thymic carcinoma, determined by subject disease response rate defined by the RECIST 1.1 criteria.

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: KN046Experimental Treatment1 Intervention

KN046 will be given intravenously every 2 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

KN046

2019

Completed Phase 2

~300

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor

1,054 Previous Clinical Trials

1,316,524 Total Patients Enrolled

Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry Sponsor

26 Previous Clinical Trials

3,027 Total Patients Enrolled

1 Trials studying Thymic Carcinoma

95 Patients Enrolled for Thymic Carcinoma

Giuseppe Giaccone, MDPrincipal InvestigatorWeill Medical College of Cornell University

1 Previous Clinical Trials

30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is the capacity for enrollment in this trial presently being reached?

"Affirmative. Based on the information from clinicaltrials.gov, this investigation is currently enrolling participants. This experimental trial was initially posted in December 2021 and recently revised in September 2022. Only 29 subjects are required for one single site to complete it successfully."

Answered by AI

Has KN046 been granted regulatory clearance by the Food and Drug Administration?

"After review, KN046 was rated 2 on the safety scale due to existing clinical data which suggests its security yet lack of evidence backing its efficacy."

Answered by AI

Are there any available spots in this clinical trial?

"According to the information present on clinicaltrials.gov, this trial is actively recruiting patients who match its inclusion criteria. The original posting for this study was published on December 13th 2021 and it has been recently updated on September 20th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

2021. "A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04925947.